TIL THERAPY VS
CAR-T THERAPY
Both use your own immune cells to fight cancer โ but they work through different biology, suit different cancer types, and carry different risks. Here is how to tell them apart.
The Core Difference
CAR-T therapy involves genetic engineering โ a new receptor programs T-cells to hunt a specific protein. When that target exists and the cancer cannot escape it, the results can be extraordinary. The limitation is real: CAR-T hunts one target. TIL therapy does not involve genetic modification โ it works with cells that already infiltrated the tumor and developed the ability to recognize multiple targets across it.
โCAR-T is precision engineering. TIL therapy is amplified biological intelligence.โ
TIL Therapy vs CAR-T Therapy: Side-by-Side
| Factor | TIL Therapy | CAR-T Therapy |
|---|---|---|
| Cell modification | No genetic changes | Genetically engineered |
| Cancer types | Solid tumors (melanoma, others) | Blood cancers (leukemia, lymphoma) |
| Tumor requirement | Needs accessible tumor tissue biopsy | Does not require tumor biopsy |
| Target specificity | Broad โ multiple tumor antigens | Narrow โ one specific antigen |
| FDA approval | Approved for melanoma (2024) | Approved for several blood cancers |
| Main toxicity risk | IL-2 toxicities, conditioning chemo | Cytokine release syndrome (CRS), ICANS |
Why TIL Therapy Has the Edge in Solid Tumors
Solid tumors create a biochemically hostile microenvironment. CAR-T cells struggle to infiltrate this dense, immune-suppressive space. TIL cells grew up in that environment โ they infiltrated it naturally. That biological advantage is why TIL therapy has a regulatory approval for melanoma (a solid tumor) while CAR-T does not. The match between therapy and tumor type is fundamental, not incidental.
Who Should Consider Each Therapy
Tumor type is the clearest dividing line. Within each category, individual eligibility depends on stage, molecular profile, and treatment history.
Consider TIL Therapy
- Solid tumor diagnosisMelanoma, lung, cervical, head and neck, ovarian โ the evidence base is growing.
- Failed prior immunotherapyTIL therapy was specifically studied and approved in patients who progressed on PD-1 blockade.
- Biopsiable tumor availableAccessible tumor tissue is required to start the manufacturing process.
Consider CAR-T Therapy
- Blood cancer diagnosisLeukemia, lymphoma, multiple myeloma โ CAR-T has approvals and established infrastructure.
- Specific antigen target presentCD19, BCMA, CD22 and others โ molecular testing confirms suitability.
- Wider center availability neededCAR-T is available at a larger number of certified centers globally.
Related TIL Therapy Topics
Explore more of the CancerFax TIL Therapy guide.
Frequently Asked Questions
TIL vs CAR-T
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Not Sure Which Cell Therapy Fits Your Diagnosis?
Upload your medical reports and get a specialist case evaluation. Our team will assess your cancer type, treatment history, and eligibility across TIL therapy and other advanced options.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.